rs35516286
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM1PM2PP3_ModeratePP5
The NM_000492.4(CFTR):c.443T>A(p.Ile148Asn) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000031 in 1,613,594 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. I148T) has been classified as Benign.
Frequency
Consequence
NM_000492.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.443T>A | p.Ile148Asn | missense_variant | 4/27 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CFTR | ENST00000003084.11 | c.443T>A | p.Ile148Asn | missense_variant | 4/27 | 1 | NM_000492.4 | ENSP00000003084.6 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152140Hom.: 0 Cov.: 32
GnomAD4 exome AF: 0.00000274 AC: 4AN: 1461454Hom.: 0 Cov.: 31 AF XY: 0.00000550 AC XY: 4AN XY: 727004
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152140Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74310
ClinVar
Submissions by phenotype
Cystic fibrosis Pathogenic:2Uncertain:3Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 13, 2024 | The p.I148N pathogenic mutation (also known as c.443T>A), located in coding exon 4 of the CFTR gene, results from a T to A substitution at nucleotide position 443. The isoleucine at codon 148 is replaced by asparagine, an amino acid with dissimilar properties. The variant has been reported to occur in cis with 5T (Silva A et al. Rev Port Pneumol (2006), 2016 Feb;22:141-5; Nunes LM et al. Pediatr Pulmonol, 2017 Oct;52:1300-1305). p.I148N in isolation or in cis with 5T has been identified in conjunction with other CFTR variant(s) in individuals with features consistent with cystic fibrosis (Hirtz S et al. Gastroenterology, 2004 Oct;127:1085-95; Silva A et al. Rev Port Pneumol (2006), 2016 Feb;22:141-5; Nunes LM et al. Pediatr Pulmonol, 2017 Oct;52:1300-1305' Maciel LMZ et al. Cad Saude Publica, 2020 Oct;36:e00049719; Ambry internal data). In an assay testing CFTR function, this variant showed a functionally abnormal result (Bihler H et al. J Cyst Fibros, 2024 Jul;23:664-675). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this variant is interpreted as a disease-causing mutation. - |
not provided, no classification provided | literature only | ClinVar Staff, National Center for Biotechnology Information (NCBI) | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 01, 2021 | This sequence change replaces isoleucine with asparagine at codon 148 of the CFTR protein (p.Ile148Asn). The isoleucine residue is moderately conserved and there is a large physicochemical difference between isoleucine and asparagine. This variant is not present in population databases (ExAC no frequency). This missense change has been observed in individual(s) with atypical cystic fibrosis and cystic fibrosis (PMID: 15480987, 28771972). ClinVar contains an entry for this variant (Variation ID: 53949). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mendelics | Sep 14, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 08, 2024 | Variant summary: CFTR c.443T>A (p.Ile148Asn) results in a non-conservative amino acid change located in the ABC transporter type 1, transmembrane domain (IPR011527) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 250526 control chromosomes. c.443T>A has been reported in the literature in the presumed compound heterozygous state in multiple individuals affected with Cystic Fibrosis or atypical Cystic Fibrosis (example, Hirtz_2004, Silva_2016,_Silva_2020, Maciel_2020). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect resulted in approximately 5.75% of normal chloride channel conductance relative to wild type (e.g., Bihler_2024). The following publications have been ascertained in the context of this evaluation (PMID: 38388235, 32084388, 33111836, 11504857, 15480987, 10571949, 28771972, 25735457, 33424627, 26898888, 32819855, 26429520). ClinVar contains an entry for this variant (Variation ID: 53949). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 22, 2021 | - - |
Cystic fibrosis;C0403814:Congenital bilateral aplasia of vas deferens from CFTR mutation Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 02, 2024 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Feb 27, 2017 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at